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he prevalence of dementia has increased with
life expectancy: more than one third of individuals over
the age of 80 are likely to develop a dementia.
1
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder that remains the most common cause of
dementia
1 and accounts for more than 60% of all cases.
2
Although AD mainly concerns aged populations, it can
also affect younger patients below 60. 
The stage at which a diagnosis of AD is made impacts the
therapy advised, the counseling given to patients and
family, and the approach to long-term care. For more
than 25 years, the diagnosis of Alzheimer’s disease has
been based on the NINCDS–ADRDA criteria,
3 accord-
ing to which the diagnosis is classified as definite (clini-
cal diagnosis with histological confirmation), probable
(typical clinical syndrome without histological confirma-
tion), or possible (atypical clinical features but no alter-
native diagnosis apparent; no histological confirmation).
The diagnosis of AD can also be based on the criteria of
the Diagnostic and Statistical Manual of Mental Disorders,
4th ed, Text Revision (DSM-IV-TR).
4 Generally speaking,
the current diagnostic criteria are characterized by a two-
step procedure with: i) the identification of a dementia
syndrome; and ii) the exclusion of other etiologies of a
dementia syndrome, using biological and neuroimaging
exams. 
The issue in AD diagnosis today is to recognize the dis-
ease before the cognitive deficits have reached the
threshold of dementia, ie, at its prodromal stage, in light
of current drug development aimed at slowing AD pro-
gression. There is a need, today, for improving the diag-
nosis of AD with a double objective: i) to reach a diagno-
sis earlier; and ii) to be more specific. 
Is it possible to make an earlier diagnosis? The answer is
yes, because Alzheimer’s disease is already symptomatic
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There has been unprecedented growth of scientific
knowledge about Alzheimer's disease (AD). The descrip-
tion of distinctive and reliable biomarkers that are now
available through structural brain imaging with mag-
netic resonance imaging, molecular neuroimaging with
positron emission tomography, and cerebrospinal fluid
analyses, and a better definition of the clinical profile of
amnestic disorders that occur early in the course of the
disease, make it possible to identify AD with high accu-
racy, even in the early stages of the disease. Accordingly,
new criteria for the diagnosis have been proposed that
capture both the prodromal and the more advanced
dementia stages of the disease in the same diagnostic
framework.  
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:135-139.long before dementia. This raises the issue of the defini-
tion of Alzheimer’s disease: what is Alzheimer’s disease?
Should it be clinically defined by a reference to demen-
tia? Should it be recognized earlier in the symptomatic
phase, before threshold of the dementia syndrome, in
case of specific cognitive changes? Can it be biologically
defined by the evidence of specific biomarkers–today
available in vivo—in the absence of any clinical symp-
toms? As we treat patients and not only lesions, we think
that AD should remain defined as a disease with a clini-
cal expression. However, it should encompass the full
spectrum of the clinical expression, including both the
predementia and dementia phases. Indeed, there is no
fundamental reason to link the diagnosis of a disease
(AD) to a certain threshold of severity and to exclude
ipso facto from the diagnostic and treatment perspectives
a large number of patients who have already expressed
the diagnosis clinically. In other words, there is no reason
to wait until the patients reach the threshold of a full-
blown dementia for making the diagnosis of Alzheimer’s
disease. It is exactly as if, in Parkinson’s disease, we
waited until the patients were bedridden to make the
diagnosis. We currently make the diagnosis of Parkinson’s
disease much earlier, when we see a resting tremor of one
hand. The same should apply for Alzheimer’s disease.
Unfortunately, the stage of predementia—or prodromal
AD—was integrated into the broad concept of mild cog-
nitive impairment (MCI), a syndrome associated with
many other causes than prodromal AD.
5,6The classical
definition of AD, restricted to the concept of dementia,
was mainly justified by the fact that the diagnosis was
more difficult to make in the early, predementia phase in
the last decades: and this was the reason for considering
it a stage of MCI. However, the emerging literature on
MCI has emphasized an intrinsic etiological heterogene-
ity and a diversity of outcomes within research studies.
Efforts to address these issues have not succeeded, and
the limitations of MCI are apparent. The risk of interven-
ing on an etiologically heterogeneous sample of MCI
subjects will include running the risk of “diluting” a sig-
nificant treatment effect.
6
Recently, research has begun to focus on developing new
tools, such as neuroimaging and cerebrospinal fluid (CSF)
biomarkers, that could increase the specificity of the prodro-
mal AD diagnosis.
7Before using such invasive or expensive
tools, it is necessary to screen patients in memory clinics with
neurological exams and neuropsychological assessment. The
most prominent feature of AD is the decline in cognitive
function. Memory impairment of recent events, unusual
repeated omissions, and difficulty learning new information
characterize the first clinical signs.
8, 9
This progression of cognitive deficits is related to the pro-
gression of the underlying cerebral lesions, as established
by Braak and Braak.
10 In the early stages of AD (Braak
I-III), critical areas for episodic memory are already
affected by neuropathological changes (neurofibrillary
degeneration) in medial temporal regions (hippocampal
formations, parahippocampal gyrus, and entorhinal cor-
tex) and, consequently, episodic memory deficit is the ini-
tial and reliable neuropsychological marker of AD. As
the condition progresses, deficits occur in instrumental
functions (language, praxis, visuospatial capacities), which
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After that initial registration has been controlled, 
a cueing (or recognition) procedure is 
recommended in case of a free recall deficit.
Total recall = free recall + cueing
(or recognition)
If total recall is low
(= marginal efficacy of cueing)
If total recall is normalized
(= good efficacy of cues)
Alzheimer's disease ￿ depression, or
￿ frontal lobe dysfunction, or
￿ subcortico-frontal dementia, or
￿ memory disorders due to sleep
   disorders, drugs or ageing…are consistent with the extension of lesions into the neo-
cortical associative areas (Braak V). 
The situation faced by clinicians is easy to summarize: i)
memory disorders are the most reliable sign of prodro-
mal AD; ii) unfortunately, memory disorders are a very
common sign, observed in many disorders: for example
in depression, anxiety, sleep disorders, brain vascular
lesions, frontal lobe dysfunction, and even in normal
aging. Is it possible, therefore, to identify the memory dis-
orders of AD? Here again, the answer is yes, because the
memory disorders of AD are not like other memory dis-
orders: there are very specific because they result from a
hippocampal dysfunction. 
This is why the neuropsychological evaluation is crucial
at the prodromal stage, for establishing the nature of
memory impairment. Specific memory tests are useful for
distinguishing the true memory impairment (eg, failure
of information storage and new memory creation) from
attentional disorders or strategic impairment (such as
normal aging or frontal disorders, Figure 1). Using a
memory test that controls for encoding and provides
semantic cueing to facilitate strategy of retrieval can
improve accuracy of AD diagnosis.
11, 12
The low performance of total recall in spite of retrieval
facilitation indicates a poor storage of information. This
amnestic syndrome that we have called “of the hippocam-
pal type”
6 differs from functional and subcorticofrontal
memory disorders, which are characterized by a low free
recall performance with normal total recall because of
good cueing efficacy. In a recent study, we showed that the
amnesic syndrome of the hippocampal type, defined by: i)
a very poor free recall; and ii) a decreased total recall due
to an insufficient effect of cueing can identify prodromal
AD in patients with MCI with a high sensitivity of 79.7%
and a specificity of 89.9%. At 36 months, the probability
of developing AD dementia for patients with MCI who
fulfilled both criteria defined by free and total recall was
90%, while it was 5.6% for those who did not fulfill both
criteria. This is not surprising, because the test used
assesses whether the given information has been truly
encoded. This should be a requirement for testing the abil-
ity to store information. How can we interpret a recall
deficit if the initial registration of information has not been
tested? Unfortunately, none of the currently used memory
tests are designed for such a test of encoding. 
The evidence of an amnestic syndrome of the hippocam-
pal type is therefore a major step for the diagnosis of pro-
dromal AD. In addition, supportive features can improve
the specificity for the diagnosis.
7 Distinctive and reliable
biomarkers of AD are now available through structural
brain imaging with magnetic resonance imaging (MRI),
molecular neuroimaging with positron emission tomog-
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Major criterion
Presence of an early and significant episodic memory impairment that includes the following features: 
1. Gradual and progressive change in memory function reported by patients or informants over more than 6 months
2. Objective evidence of significantly impaired episodic memory on testing: this generally consists of recall deficit that does not improve 
significantly, or does not normalize with cueing or recognition testing and after effective encoding of information has been previously
assessed
3. The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of AD or as AD advances.
Minor criteria:
A- Presence of medial temporal lobe atrophy 
￿ Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with:
Qualitative ratings using visual scoring (referenced to well characterized population with age norms) or quantitative volumetry of 
regions of interest (referenced to well characterized population with age norms)
B- Abnormal CSF biomarkers: 
￿ Low amyloid β 1-42 concentrations, increased total tau and/or increased phospho-tau concentrations
￿ Other well-validated markers to be discovered in the future
C. Specific pattern on functional neuroimaging with PET:
￿ Reduced glucose metabolism in bilateral temporal parietal regions
￿ Other well-validated ligands, including those that forseeably will emerge such as PiB or FDDNP. 
D. Proven AD autosomal dominant mutation within the immediate family
Table I. New diagnostic criteria for Alzheimer´s disease (AD): 1 major criterion plus 1 (or more) minor criterion. MRI, magnetic resonance imaging;
CSF, cerebrospinal fluid; PET, positron emission tomography; PiB, Pittsburgh compound B; FDDNP, amyloid ligandraphy (PET) and CSF, analysis of A-beta 42 concentra-
tion, total tau and phospho-tau levels. The presence of at
least one biological footprint of the disease should
improve the specificity for the diagnosis. This is at the ori-
gin of the new diagnostic criteria that were proposed in
2007
7 (Table I). These criteria no longer refer to the
dementia threshold. They move away from the tradi-
tional two-step approach of first identifying dementia
according to degree of functional disability and then
specifying its cause. Rather, they aim to define the clini-
cal, biochemical, structural, and metabolic presence of
AD, even at early stages. Therefore, we consider that the
new diagnostic criteria which capture the early prede-
mentia phase of the disease reach the two objectives: to
be earlier and to be more specific. According to these cri-
teria, the diagnosis of early AD can be made on the
objective evidence of significantly impaired memory
upon testing, and the presence of hippocampal atrophy
on MRI, or an abnormal pattern of CSF biomarkers, or
a specific pattern on PET neuroimaging. We recognize
that these criteria represent a cultural shift requiring a
more biologically focused workup than previous
approaches; however, this seems to be the best way to
integrate the profound advances into the clinical arena.
When effective disease-modifying medications are avail-
able, the argument for such biologically based studies will
be even more compelling. Some research needs will be
better addressed with a more stringent approach requir-
ing that each diagnostic criterion be met. For example,
proof-of-concept studies may benefit from the most
highly selected AD study samples where the presence of
all supportive features might be specified. This could
maximize specificity for AD, but impose a substantial loss
of sensitivity that would need to be readdressed in later
stages of development. Their usefulness of these new cri-
teria will be determined in the future as investigators
apply the criteria in a variety of research studies, and as
key issues in their application are resolved. ❏
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Detección precoz de la Enfermedad de
Alzheimer: nuevos criterios diagnósticos
Ha habido un crecimiento sin precedentes acerca
del conocimiento científico de la Enfermedad de
Alzheimer (EA). Tanto la descripción de biomarca-
dores característicos y confiables de los cuales se dis-
pone actualmente a través de las imágenes cerebra-
les estructurales de la resonancia magnética, de las
neuroimágenes moleculares de la tomografía por
emisión de positrones y del análisis del líquido
céfalo-raquídeo, como una mejor definición del
perfil clínico de los trastornos amnésicos que se pro-
ducen precozmente durante la evolución de esta
patología, permiten identificar la EA con bastante
precisión, aun en etapas precoces de la enferme-
dad. De acuerdo con esto, se han propuesto nuevos
criterios para el diagnóstico que centran la atención
tanto en las etapas prodrómicas como en las etapas
de demencia más avanzadas de la enfermedad den-
tro del mismo esquema diagnóstico.
Détection précoce de la maladie d’Alzheimer :
nouveau critère diagnostique
La connaissance scientifique de la maladie
d’Alzheimer (MA) a fait récemment des progrès
importants. Il est maintenant possible d’identifier
la MA avec précision, même aux stades précoces de
la maladie, grâce à la mise en évidence de biomar-
queurs caractéristiques et fiables désormais dispo-
nibles par imagerie cérébrale structurale avec
l’imagerie par résonance magnétique, la neuro-
imagerie moléculaire par tomographie par émission
de positons et l’analyse du liquide céphalo-rachi-
dien, ainsi qu’une meilleure définition du profil cli-
nique des troubles mnésiques intervenant de façon
précoce au cours de la maladie. De nouveaux cri-
tères de diagnostic ont par conséquent été propo-
sés pour appréhender à la fois les stades prodro-
maux ou prédémentiels et les stades plus avancés
de la maladie dans le même cadre diagnostique.Early detection of AD - Dubois et al Dialogues in Clinical Neuroscience - Vol 11 . No. 2 . 2009
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